# Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

> **NCT03700476** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 425 (actual)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **RADIATION:** intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT03700476
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-21
- **Primary completion:** 2023-02-28
- **Final completion:** 2025-01
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2023-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700476, "Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03700476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*